- Details
- Description
About Glumetinib or Gumarontinib
Glumetinib (SCC244) also named Gumarontinib， is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor.Glumetinib has excellent pharmacokinetic characteristics with long half-life and high steady-state trough concentration in human body, which is conducive to the continuous inhibition of the target.
- Glumetinib sold as brand name 海益坦® in china.
- Gumarontinib sold as brand name ハイイータン® in Japan.
Approval
In June 2024, the MET inhibitor Glumetinib tablets were approved for marketing by the Ministry of Health, Labor and Welfare of Japan for the treatment of locally advanced or metastatic non-small cell lung cancer with MET exon 14 mutations.
《MET阻害剤「ハイイータン® 錠50 mg」MET遺伝子エクソン14スキッピング変異陽性の切除不能な進行・再発の非小細胞肺癌に対する製造販売承認を取得》
Dosage and administration
The recommended dose of Glumetinib is 80 mg, taken orally once a day until disease progression or intolerable toxicity occurs.
Glumetinib should be taken on an empty stomach. Take Glumetinib at approximately the same time every day, swallow the whole tablet with water, do not crush or chew. If the patient misses a dose of Glumetinib and the next dose is more than 12 hours away, the patient should take Glumetinib.
Dose adjustment
If adverse events occur during the use of Glumetinib, the drug can be temporarily interrupted, the dose can be reduced, or the treatment with Glumetinib can be stopped according to the specific situation. If a reduction in dose is required, the dose can be reduced to 40 mg, once a day.
